Lenacapavir + bNAbs Combo Therapy Shows Promise in HIV Phase 2 Trial
“`html
Novel HIV Therapy Combining Lenacapavir and Broadly Neutralizing antibodies Shows Promise
Table of Contents
A phase 2 clinical trial presented at the European AIDS Conference (EACS) 2025 suggests a new combination therapy-lenacapavir (LEN) plus two broadly neutralizing antibodies (bNAbs)-is effective and well-tolerated for certain HIV patients. The findings offer a potential alternative to daily oral antiretroviral regimens.
Source: Infectious Disease Special Edition
Last Updated: October 18,2025,19:23:17 (EST)
Key Findings of the Phase 2 Trial
Researchers presented the results of the phase 2 trial (abstract PS09.2) at EACS 2025, held in Paris. The trial,identified by ClinicalTrials.gov Identifier: NCT05729568, evaluated the efficacy and safety of combining lenacapavir (LEN, Gilead) with teropavimab (TAB, Gilead) and zinlirvimab (ZAB, Gilead). The combination therapy demonstrated comparable CD4+ cell count increases to those seen with standard daily oral antiretroviral regimens (SBR).
Specifically, the study found that LEN, when administered with TAB and ZAB, resulted in a slight, but not statistically significant, decrease in average CD4+ count increases compared to a stable SBR. Importantly, the vast majority of participants maintained a consistently undetectable viral load-less than 50 copies/mL-throughout the 52-week study period.
Understanding the Components
This novel approach combines three distinct mechanisms to combat HIV:
- Lenacapavir (LEN): A first-in-class capsid inhibitor developed by Gilead Sciences. It prevents the virus from assembling and infecting cells.
- Teropavimab (TAB): A broadly neutralizing antibody (bNAb) that targets the HIV envelope protein, preventing the virus from entering cells.
- Zinlirvimab (ZAB): Another bNAb, also targeting the HIV envelope protein, offering a second layer of neutralization.
Broadly neutralizing antibodies are notably exciting because they can neutralize a wide range of HIV strains, unlike some conventional antibodies.Combining two bNAbs further reduces the risk of viral escape due to mutations.
Implications for HIV Treatment
The data presented at EACS 2025 represent a significant step forward in exploring alternative treatment strategies for HIV. While daily oral antiretroviral therapy remains the standard of care, it requires lifelong adherence. Long-acting injectable therapies and now, combinations like LEN plus bNAbs, offer the potential for less frequent dosing and improved convenience.
Brian Plummer, a spokesperson for Gilead, expressed optimism about the findings, stating that the data presented at EACS is the first time the combination’s efficacy has been demonstrated.This suggests a potential pathway for a new treatment option for individuals living with HIV.